Have clinical studies demonstrated diabetes prevention or delay of diabetes through early treatment?

American Journal of Therapeutics

Volumn 17, Issue 2, 2010, Pages 201-209

  Southwood, Robin L ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Acarbose; Diabetes prevention; Metformin; Orlistat; Pharmacologic; Prediabetes; Ramipril; Rosiglitazone; Troglitazone; Voglibose

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TROGLITAZONE; VOGLIBOSE;

AEROBIC EXERCISE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET ALPHA CELL; PATIENT COMPLIANCE; POSTPRANDIAL STATE; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; LIFE STYLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 77949963642     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181b64aa1     Document Type: Review

References (41)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
2. American Diabetes Association. Total Prevalence of Diabetes & Pre-diabetes. American Diabetes Association website. Available at: http://www.diabetes.org/diabetesstatistics/ prevalence.jsp. Accessed May 15, 2008.
3. Mainous AG, Baker R, Koopman RJ, et al. Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way. Diabetologia. 2007;50:934-940.
4. Kung HC, Hoyert DL, Xu J, et al. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56:1-120.
5. Almdal T, Scharling H, Jensen JS, et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164:1422-1426.
6. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44:S14-S21.
7. Franco OH, Steyerberg EW, Hu FB, et al. Associations of Diabetes Mellitus with Total Life Expectancy and Life Expectancy With and Without Cardiovascular Disease. Arch Intern Med. 2007;167:1145-1151.
8. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-1134.
9. Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975-980.
10. Qiao Q, Tuomilehto J, Moltchanova E, et al. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003;26:688-696.
11. Selvin E, Marinopoulos S, Berkenblit G, et al. Glycated hemoglobin and cardiovascular disease in diabetes: A systematic review. Diabetes. 2003;52:A166-A66.
12. Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A(1c) with cardiovascular disease and mortality in adults: The European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141:413-420.
13. Hirai FE, Moss SE, Klein BE, et al. Relationship of glycemic control, exogenous insulin, and C-peptide levels to ischemic heart disease mortality over a 16-year period in people with older-onset diabetes: The Wisconsin Epidermologic Study of Diabetic Retinopathy (WESDR). Diabetes Care. 2008;31:493-497.
14. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596-615.
15. Garber AJ, Handelsman Y, Einhorn D. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14:933-946.
16. Sherwin RS, Anderson RM, Buse JB, et al. The prevention or delay of type 2 diabetes. Diabetes Care. 2002;25:742-749.
17. Buchanan TA. Prevention of type 2 diabetes: What is it really? Diabetes Care. 2003;26:1306-1308.
18. Azen SP, Peters RK, Berkowitz K, et al. TRIPOD (TRoglitazone in the Prevention of Diabetes): A randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials. 1998;19:217-231.
19. Chiasson JL, Gomis R, Hanefeld M, et al. The STOPNIDDM Trial-An international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Diabetes Care. 1998;21:1720-1725.
20. Bray GA, Culbert IW, Champagne CM, et al. The Diabetes Prevention Program - Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623-634.
21. Ramachandran A, Snehalatha C, Mukesh B, et al. Persistent impaired glucose tolerance has similar rate of risk factors as for diabetes: Results of Indian Diabetes Prevention Programme (IDPP). Diabetes Res Clin Pract. 2006;73:100-103.
22. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27:155-161.
23. Gerstein HC, Yusuf S, Holman R, et al. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia. 2004;47:1519-1527.
24. Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373:1607-1614.
25. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.
26. Xiang AH, Peters RK, Kjos SL, et al. Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. J Clin Endocrinol Metab. 2005;90:1986-1991.
27. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial. Lancet. 2002;359:2072-2077.
28. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOPNIDDM Ttrial. JAMA. 2003;290:486-494.
29. Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35:1073-1078.
30. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
31. Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. Diabetes. 2005;54: 2404-2414.
32. Knowler WC, Hamman RF, Edelstein SL, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54:1150-1156.
33. Knowler WC, Barrett-Connor E, Fowler SE, et al. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care. 2003;26:977-980.
34. Ratner R, Goldberg R, Haffner S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care. 2005;28:888-894.
35. Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian-Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289-297.
36. Gerstein HC, Yusuf S, Holman RR, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105.
37. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355: 1551-1562.
38. Buchanan TA, Xiang AH, Kjos SL, et al. Diabetes rates and B-cell function in the pioglitazone in prevention of diabetes (PIPOD) study. Diabetes. 2005;54:A39-A39.
39. Zinman B, Harris SB, Gerstein HC, et al. Preventing type 2 diabetes using combination therapy: design and methods of the Canadian Normoglycaemia Outcomes Evaluation (CANOE) trial. Diabetes Obes Metab. 2006;8: 531-537.
40. FDA. Pioglitazone HCl Information. CDER. 2007.
41. FDA. Information for Healthcare Professionals, Rosiglitazone maleate. 2007.